Historical Valuation
Acrivon Therapeutics Inc (ACRV) is now in the Overvalued zone, suggesting that its current forward PS ratio of 600.35 is considered Overvalued compared with the five-year average of -2.66. The fair price of Acrivon Therapeutics Inc (ACRV) is between 0.43 to 1.54 according to relative valuation methord. Compared to the current price of 1.93 USD , Acrivon Therapeutics Inc is Overvalued By 25.39%.
Relative Value
Fair Zone
0.43-1.54
Current Price：1.93
25.39%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Acrivon Therapeutics Inc (ACRV) has a current Price-to-Book (P/B) ratio of 0.60. Compared to its 3-year average P/B ratio of 1.10 , the current P/B ratio is approximately -44.91% higher. Relative to its 5-year average P/B ratio of 1.03, the current P/B ratio is about -41.53% higher. Acrivon Therapeutics Inc (ACRV) has a Forward Free Cash Flow (FCF) yield of approximately -87.68%. Compared to its 3-year average FCF yield of -54.83%, the current FCF yield is approximately 59.92% lower. Relative to its 5-year average FCF yield of -52.78% , the current FCF yield is about 66.14% lower.
P/B
Median3y
1.10
Median5y
1.03
FCF Yield
Median3y
-54.83
Median5y
-52.78
Competitors Valuation Multiple
AI Analysis for ACRV
The average P/S ratio for ACRV competitors is 161.23, providing a benchmark for relative valuation. Acrivon Therapeutics Inc Corp (ACRV.O) exhibits a P/S ratio of 600.35, which is 272.36% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ACRV
1Y
3Y
5Y
Market capitalization of ACRV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ACRV in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ACRV currently overvalued or undervalued?
Acrivon Therapeutics Inc (ACRV) is now in the Overvalued zone, suggesting that its current forward PS ratio of 600.35 is considered Overvalued compared with the five-year average of -2.66. The fair price of Acrivon Therapeutics Inc (ACRV) is between 0.43 to 1.54 according to relative valuation methord. Compared to the current price of 1.93 USD , Acrivon Therapeutics Inc is Overvalued By 25.39% .
What is Acrivon Therapeutics Inc (ACRV) fair value?
ACRV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Acrivon Therapeutics Inc (ACRV) is between 0.43 to 1.54 according to relative valuation methord.
How does ACRV's valuation metrics compare to the industry average?
The average P/S ratio for ACRV's competitors is 161.23, providing a benchmark for relative valuation. Acrivon Therapeutics Inc Corp (ACRV) exhibits a P/S ratio of 600.35, which is 272.36% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Acrivon Therapeutics Inc (ACRV) as of Jan 09 2026?
As of Jan 09 2026, Acrivon Therapeutics Inc (ACRV) has a P/B ratio of 0.60. This indicates that the market values ACRV at 0.60 times its book value.
What is the current FCF Yield for Acrivon Therapeutics Inc (ACRV) as of Jan 09 2026?
As of Jan 09 2026, Acrivon Therapeutics Inc (ACRV) has a FCF Yield of -87.68%. This means that for every dollar of Acrivon Therapeutics Inc’s market capitalization, the company generates -87.68 cents in free cash flow.
What is the current Forward P/E ratio for Acrivon Therapeutics Inc (ACRV) as of Jan 09 2026?
As of Jan 09 2026, Acrivon Therapeutics Inc (ACRV) has a Forward P/E ratio of -1.24. This means the market is willing to pay $-1.24 for every dollar of Acrivon Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Acrivon Therapeutics Inc (ACRV) as of Jan 09 2026?
As of Jan 09 2026, Acrivon Therapeutics Inc (ACRV) has a Forward P/S ratio of 600.35. This means the market is valuing ACRV at $600.35 for every dollar of expected revenue over the next 12 months.